Neuroendocrine Neoplasm Clinical Trial
Official title:
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of High-grade Advanced-neuroendocrine Neoplasms: a Single Arm, Open-label, Multi Center, Phase II Study
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Sintilimab combined with IBI310 and Surufatinib for the treatment of high-grade advanced-neuroendocrine neoplasm
The study population is about 40 patients with high-grade advanced-neuroendocrine neoplasm, who fails or cannot tolerate standard therapies. Surufatinib 250 mg once a day (QD) will be orally administrated, Sintilimab 200mg will be intravenously administered every 3 weeks and IBI310 1mg/kg will be intravenously administered every 6 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. For Sintilimab, the upper time limit for treatment is 2 years. The primary objective is objective response rate (ORR) of Sintilimab combined with IBI310 and Surufatinib in patients with advanced high-grade advanced-neuroendocrine neoplasm. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
| Active, not recruiting |
NCT03375320 -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 3 | |
| Active, not recruiting |
NCT03980925 -
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
|
Phase 2 | |
| Recruiting |
NCT02402244 -
Project: Every Child for Younger Patients With Cancer
|
||
| Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
| Recruiting |
NCT05879055 -
A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN
|
Phase 2 | |
| Terminated |
NCT03001349 -
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
|
Early Phase 1 | |
| Completed |
NCT02399215 -
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Recruiting |
NCT06337760 -
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
|
||
| Recruiting |
NCT04927611 -
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
|
||
| Active, not recruiting |
NCT01638533 -
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
Phase 1 | |
| Recruiting |
NCT02817945 -
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
|
Early Phase 1 | |
| Active, not recruiting |
NCT03950609 -
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT04750954 -
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02402920 -
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT04931446 -
Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis
|
||
| Recruiting |
NCT06343428 -
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
|
||
| Recruiting |
NCT04720391 -
Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
|
||
| Recruiting |
NCT03734913 -
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03511768 -
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
|
Phase 1/Phase 2 |